Overview

A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis

Status:
Completed
Trial end date:
2019-04-04
Target enrollment:
Participant gender:
Summary
This is a double-blind, pilot study with 20 subjects to determine the tolerability and efficacy of topical AFX 5931 in the treatment of mild to moderate hand dermatitis. Subjects are screened up to 30 days before the baseline visit. Subjects who meet the eligibility criteria may qualify for the study. Subjects will be randomized in a 3:1 ratio to receive either the active or vehicle medication. 15 subjects will receive the active, therapeutic product and 5 subjects will receive the inactive, vehicle product.
Phase:
Phase 4
Details
Lead Sponsor:
The Center for Clinical and Cosmetic Research
Collaborator:
Afecta Pharmaceuticals